Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
NU E Power Corp. Announces Closing of Non-Brokered Private Placement for $1.7 Million. (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Thiogenesis Therapeutics Corp V.TTI

Alternate Symbol(s):  TTIPF

Healthcare Biotechnology
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated... see more

Current News (TSXV:TTI)

Thiogenesis Therapeutics' MELAS Abstract Accepted for Late-Breaking News Presentation at Mitocon 2026

Newsfile 8 days ago

Thiogenesis to Present Clinical Updates in MELAS and Leigh Syndrome Spectrum at UMDF Bench-to-Bedside Webinar

Newsfile January 5, 2026

Thiogenesis Therapeutics Expands on Plans for Phase 3 Pivotal Trial of TTI-0102 in Nephropathic Cystinosis

Newsfile November 24, 2025

Thiogenesis Reports Positive Interim Phase 2 Trial Results for MELAS and Announces Pipeline Advancements in Leigh Syndrome and Cystinosis

Newsfile November 4, 2025

Thiogenesis Announces Extension to Investor Relations Agreement

Newsfile October 3, 2025

Thiogenesis Reports on 2025 Annual General Meeting of Shareholders and Provides Corporate Update

Newsfile September 11, 2025

Thiogenesis Receives Final Acceptance from TSXV for Its Over-Subscribed Non-Brokered Private Placement of Common Shares

Newsfile August 14, 2025

Thiogenesis Raises over C$4.14 Million in Non-Brokered Private Placement of Common Shares

Newsfile August 1, 2025

Thiogenesis Upsizes Fully Subscribed Non-Brokered Private Placement of Common Shares

Newsfile July 29, 2025
View More News ››

Opinion & Analysis (TSXV:TTI)

No current opinion is available.
View More Opinion ››

Bullboard Posts (TSXV:TTI)

MELAS Abstract Accepted for Late-Breaking News Presentation

Posted on behalf of Thiogenesis Therapeutics Corp. – Today, Thiogenesis Therapeutics (TTI.v TTIPF) announced that an abstract outlining...
MarketMakerss - 8 days ago

Targeting Severe Mitochondrial Diseases

Posted on Behalf of Thiogenesis Therapeutics Corp. –  Thiogenesis Therapeutics (TTI.v TTIPF) is advancing a focused clinical...
MarketMakerss - January 7, 2026

TTI Initiating Phase 3 Clinical Trials of TTI-0102

Posted on behalf of Thiogenesis Therapeutics Corp. - Last week Thiogenesis Therapeutics Corp. (TTI.v TTIPF) announced plans to initiate...
SkywalkerofLuke - December 5, 2025

TTI Shares Phase 3 Nephropathic Cystinosis Plans

Posted on behalf of Thiogenesis Therapeutics, Corp. - Thiogenesis Therapeutics, Corp. (Ticker: TTI.v or TTIPF for US investors...
1StockInformer - November 25, 2025

Phase 3 Trial of TTI-0102 Announced Today

Posted on Behalf of Thiogenesis Therapeutics Corp. - Today, Thiogenesis Therapeutics (TTI.v TTIPF) announced plans to initiate a Phase...
MarketMakerss - November 24, 2025

Phase 2 Highlights (MELAS)

Thiogenesis Therapeutics (TTI.v | TTIPF): Positive Phase 2 MELAS Data Strengthens Rare-Disease Pipeline Momentum Posted on behalf of...
JazzLover444 - November 20, 2025
View more Bullboard ››

Lithium Ionic Corp

Lithium Ionic Corp

Lithium Ionic Corp., together with its subsidiaries, engages in the acquisition, exploration, and development of lithium ...
View More »

Podcasts